BioMarin Pharmaceutical Inc. (BMRN) financial statements (2020 and earlier)

Company profile

Business Address 105 DIGITAL DRIVE
NOVATO, CA 94949
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7541,0841,396790593945785
Cash and cash equivalents437494598408397875569
Short-term investments31659079838119670216
Restricted cash and investments     2 
Receivables377343261215165191118
Inventory, net of allowances, customer advances and progress billings680531476355272199163
Inventory680531476355272199163
Prepaid expense     29 
Deferred costs     1215
Derivative instruments and hedges, assets     11 
Other current assets1319874626010542
Other undisclosed current assets     (69)15
Total current assets:1,9422,0562,2071,4221,0901,4261,137
Noncurrent Assets
Property, plant and equipment1,011949897799704524319
Long-term investments and receivables41223638657342698268
Long-term investments41223638657342698268
Intangible assets, net (including goodwill)654689715751881211217
Goodwill1971971971971975454
Intangible assets, net (excluding goodwill)457492518554684157163
Derivative instruments and hedges     5 
Deposits noncurrent assets     127
Restricted cash and investments      0
Deferred income tax assets549
Other noncurrent assets12237303340965156
Other undisclosed noncurrent assets 461399447220150144
Total noncurrent assets:2,7482,3712,4262,6022,6401,0651,112
TOTAL ASSETS:4,6904,4274,6334,0243,7292,4902,249
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:571437402371393236183
Accounts payable     3337
Accrued liabilities31635550439858
Employee-related liabilities192150141109784533
Taxes payable88108654
Other undisclosed accounts payable and accrued liabilities3392161962042655451
Debt362 36122   
Deferred compensation liability     21
Business combination, contingent consideration, liability 86544653 
Deferred revenue and credits   11
Other undisclosed current liabilities     (3)(2)
Total current liabilities:933523817439445236183
Noncurrent Liabilities
Long-term debt and lease obligation486830814661662658656
Long-term debt, excluding current maturities486830814661662658656
Liabilities, other than long-term debt1491061941572213039
Deferred tax liabilities, net   144  
Other liabilities98595942453039
Business combination, contingent consideration, liability514713511533 
Other undisclosed noncurrent liabilities     3931
Total noncurrent liabilities:6359361,008818883727725
Total liabilities:1,5681,4591,8241,2571,329963908
Stockholders' equity
Stockholders' equity attributable to parent, including:3,1222,9682,8092,7662,4011,5281,341
Common stock0000000
Additional paid in capital4,8334,6704,4834,2883,4152,3602,059
Accumulated other comprehensive income (loss)205(23)1321275
Accumulated deficit(1,721)(1,694)(1,638)(1,521)(1,022)(850)(716)
Other undisclosed stockholders' equity attributable to parent(10)(13)(14)(14)(14)(10)(7)
Total stockholders' equity:3,1222,9682,8092,7662,4011,5281,341
TOTAL LIABILITIES AND EQUITY:4,6904,4274,6334,0243,7292,4902,249

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues1,7041,4911,3141,117890751548
Revenue, net1,3141,117890751548
Cost of revenue(359)(315)(242)(210)(152)(130)(96)
Gross profit:1,3451,1761,072907738621453
Operating expenses(1,371)(1,251)(1,040)(1,138)(668)(753)(638)
Other operating income, net     01
Other undisclosed operating income (loss)(74)(49)(46)(572)(181)3929
Operating loss:(100)(124)(15)(803)(111)(93)(156)
Nonoperating income224192224173
Investment income, nonoperating2323157563
Gain on contract termination     10 
Foreign currency transaction gain (loss), before tax(1)18(6)14201 
Interest and debt expense(23)(44)(43)(39)(38)(37)(23)
Other undisclosed loss from continuing operations before equity method investments, income taxes     (12)(0)
Loss from continuing operations before equity method investments, income taxes:(102)(127)(49)(821)(125)(125)(177)
Loss from equity method investments(1)(1)(1)(1)(1)(1)(1)
Other undisclosed income (loss) from continuing operations before income taxes8(16)14(10)(29)  
Loss from continuing operations before income taxes:(95)(143)(36)(831)(155)(126)(178)
Income tax expense (benefit)7165(81)201(17)(9)0
Net loss:(24)(77)(117)(630)(172)(135)(178)
Other undisclosed net income attributable to parent     11
Net loss available to common stockholders, basic:(24)(77)(117)(630)(172)(134)(176)
Other undisclosed net loss available to common stockholders, diluted (1) (3)   
Net loss available to common stockholders, diluted:(24)(78)(117)(633)(172)(134)(176)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(24)(77)(117)(630)(172)(135)(178)
Other comprehensive income (loss)1529(36)(8)(6)225
Comprehensive loss:(9)(48)(153)(638)(178)(112)(172)
Other undisclosed comprehensive income, net of tax, attributable to parent     11
Comprehensive loss, net of tax, attributable to parent:(9)(48)(153)(638)(178)(112)(171)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: